Objetivo
In order to meet the expanding market for human stem cells (HSCs) in cell therapy, automated, cost-effective, large-scale manufacturing processes are required. AGLARIS Project is centered in the market launch of the patented AGLARIS BIOREACTOR for large-scale HSCs production, which perfectly meets the requirements for cell-based therapeutic products. Current bioreactors for HSCs producers consist in attempts to adapt bioreactors derived from traditional bioprocesses, but its use has not been widespread as they are not optimized for HSCs production. The automation level of bioreactors is limited to an initial quantity of 20M cells. As the cell sample from biopsies contains 0.5-1M cells, a previous manual cultivation is always required to reach the minimum quantity. This step affects cell quality. AGLARIS operates with the quantity of cells coming directly from biopsy, completely eliminating the manual pre-cultivation requirement. Moreover, current Bioreactors are limited to 300M cells per cell batch. The common are based on hollow-fibers as the substrate in which cells are anchored for growing. Once they reach its maximum capacity, cells need to be detached by using chemical and enzymatic reagents. AGLARIS operates in an iterative manner reaching 5000M cells without dividing the cultivation process in several batches. It is based on microcarriers which allows cell detachment by a simply small variation of temperature, avoiding adverse side effects. Additionally, for a complete disease management, the production of 600M cells on average is required. When produced manually, the cultivation of 600M cells can reach 9.347€, and by using hollow-fiber Bioreactors 15.643€. AGLARIS optimized culture process produces cell yields with the correct quality while using minimal amounts of expensive reagents, allowing the price to decrease to 1.015€ per 600 M of cells, meaning that costs will be reduced by up to 91% on average.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- engineering and technologymechanical engineeringmanufacturing engineering
- engineering and technologyenvironmental biotechnologybioremediationbioreactors
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEINST-1-2016-2017
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
SG1 2FX Stevenage
Reino Unido
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.